Investing in Concert Pharmaceuticals, Inc. (CNCE)  ➔  Intrinsic value

Prev. close$3.71 
ModelValueUpside
Chepakovich$3.58-3%
Graham-Dodd$0.00-100%
Graham$41.82+1,027%
Previous Close$3.71  
Valuation MethodValuePotential 
Chepakovich Model$3.58-3%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$41.82+1,027%recalculate

Latest news

Company description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.